Improving the care of Lassa fever patients: re-evaluating the use of Ribavirin and characterising cardiovascular function
<p>Lassa fever is a viral haemorrhagic fever, endemic to several West African countries. Case fatality rates average 30% across the literature. Ribavirin, a broad-spectrum antiviral agent, has been used to treat Lassa fever for four decades. Ribavirin is a pro-drug, metabolised to its active m...
| Päätekijä: | |
|---|---|
| Muut tekijät: | |
| Aineistotyyppi: | Opinnäyte |
| Kieli: | English |
| Julkaistu: |
2024
|
| Aiheet: |